Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

• DOI: 10.1359/jbmr.2003.18.6.1051
• Publication Date: 2006-04-26T23:31:38Z
• Authors: R Eastell; I Barton; Ra Hannon; A Chines; P Garnero; Pd Delmas
• Keywords: Bone remodeling; Strontium ranelate; Etidronic acid; N-terminal telopeptide; Alendronic acid

Abstract Changes in the level of biochemical markers bone resorption with risedronate treatment for osteoporosis were examined as a surrogate decrease fracture risk. Greater decreases associated greater vertebral (and nonvertebral) fractures. Antifracture efficacy antiresorptive therapies is only partially explained by increases mineral density. Early may also play role. We tested this hypothesis measuring two markers, C-telopeptide type I collagen (CTX) and N-telopeptide (NTX), osteoporotic patients trials. studied 693 women at least one deformity (mean age, 69 ± 7 years) who received calcium vitamin D if required) placebo or 5 mg daily 3 years. The reductions urinary CTX (median, 60%) NTX (51%) 3-6 months therapy significantly (p < 0.05) reduction risk (75% over 1 year 50% years). changes both accounted approximately one-half (CTX, 55%; NTX, 49%) risedronate's effect reducing fractures first two-thirds 67%; 66%) years compared placebo. 77% 54%, respectively, nonvertebral relationships between from baseline not linear 0.05). There was little further improvement benefit below 55-60% 35-40% NTX. taking accounts large proportion be which there no benefit.